Bain, Cinven buy Lonza Specialty Ingredients in $4.7 billion deal ZURICH (Reuters) – Bain Capital and Cinven are acquiring Lonza’s Specialty Ingredients division in a deal worth $4.7 billion, the Swiss contract drug [...]